Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Vaccitech PLC banner

Vaccitech PLC
F:2AB

Watchlist Manager
Vaccitech PLC Logo
Vaccitech PLC
F:2AB
Watchlist
Price: 0.565 EUR -0.88% Market Closed
Market Cap: €22.1m
Write Note Create Alert Ask AI

Vaccitech PLC
Goodwill

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also
Balance Sheet

Vaccitech PLC
Goodwill Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Goodwill CAGR 3Y CAGR 5Y CAGR 10Y
Vaccitech PLC
F:2AB
Goodwill
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Compass Pathways PLC
NASDAQ:CMPS
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Goodwill
£102.8m
CAGR 3-Years
-3%
CAGR 5-Years
-1%
CAGR 10-Years
3%
Oxford BioMedica PLC
LSE:OXB
Goodwill
£0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Vaccitech PLC
Glance View

Market Cap
22.1m EUR
Industry
Biotechnology

Vaccitech Plc operates as a holding company. The company is headquartered in Oxford, Oxfordshire and currently employs 72 full-time employees. The company went IPO on 2021-04-30. The firm is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The firm uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The firm has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

2AB Intrinsic Value
HIDDEN
Show
What is Intrinsic Value?

See Also

What is Vaccitech PLC's Goodwill?
Goodwill
0 USD

Based on the financial report for Dec 31, 2024, Vaccitech PLC's Goodwill amounts to 0 USD.

Back to Top
ALPHA SPREAD
Follow us
Join more than 317,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.